InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
Auto-immune
Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...
Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm
China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...
Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis
German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...
Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...
Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...
IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD
China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...
Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China
China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...
Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy
Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...
Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...
Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...
RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis
China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...